Skip to main content
TipRanks
Go Ultimate75% OFF

Oragenics (0A64) Drug Pipeline

1 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Neurosteroid EnantiomerMild Traumatic Brain Injury, ConcussionPhase IINot Yet RecruitingA Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain InjuryMar 05, 2025―
Ag013Oral MucositisPhase IITerminatedEfficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per DayJul 21, 2017―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Oragenics Inc (GB:0A64) have in its pipeline
Oragenics GB:0A64 is currently developing the following drugs: Neurosteroid Enantiomer, Ag013. These drug candidates are in various stages of clinical development as the company works toward FDA approval.